1989
DOI: 10.1111/j.1749-6632.1989.tb46664.x
|View full text |Cite
|
Sign up to set email alerts
|

A Summary of the Current Position of TRH in ALS Therapy

Abstract: The critical points that must be addressed in evaluating ergotropic drugs are exemplified by the current morass of positive and negative results that have been obtained in clinical investigations of TRH or its analogues. Appropriate subject selection is crucial. These patients may have bulbar symptoms, and those features of ALS should be specifically assayed for treatment effects relative to placebo. Gender-specific effects of TRH need to be accounted for in study design. In addition, electrophysiological tech… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1990
1990
2018
2018

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 17 publications
(2 citation statements)
references
References 61 publications
0
2
0
Order By: Relevance
“…It stimulates motor neurons, and thus could be important in the treatment of motor neuron diseases. Some improvements, after treatment with TRH, were seen in patients with ALS (amyotrophic lateral sclerosis) and spinocerebellar degeneration [6,21,34]. TRH could elevate the activity of the sympathetic and parasympathetic nervous system, but these effects are dosedependent.…”
Section: Stimulatory Effects Of Trh In the Cns And Its Potential Clinmentioning
confidence: 99%
“…It stimulates motor neurons, and thus could be important in the treatment of motor neuron diseases. Some improvements, after treatment with TRH, were seen in patients with ALS (amyotrophic lateral sclerosis) and spinocerebellar degeneration [6,21,34]. TRH could elevate the activity of the sympathetic and parasympathetic nervous system, but these effects are dosedependent.…”
Section: Stimulatory Effects Of Trh In the Cns And Its Potential Clinmentioning
confidence: 99%
“…However, another role of TRH as a neuropeptide is underestimated (Gary et al, 2003; Khomane et al, 2011). TRH has long ago been proved useful in multiple animal models of diseases such as brain/spinal cord injuries (Faden et al, 1981; Pitts et al, 1995), depression (Szuba et al, 1995; Marangell et al, 1997), epilepsy (Jaworska-Feil et al, 2001; Kubek et al, 2009), schizophrenia (Wilson et al, 1973), amyotrophic lateral sclerosis (ALS; Hawley et al, 1987; Brooks, 1989), Alzheimer’s disease (AD; Mellow et al, 1989; Molchan et al, 1990) and Parkinson’s disease (PD; Ogata et al, 1998). However, TRH has the intrinsic shortcomings such as short half-life, poor lipophilicity and strong HPT axis stimulating effect, which severely restrict its application (Kinoshita et al, 1998).…”
Section: Introductionmentioning
confidence: 99%